Lilly's Jaypirca Slashes CLL/SLL Progression Risk by 45% in Key Trial
LLY sits 82% above its 52-week low of $623.78.
Summary
Eli Lilly announced positive clinical trial results for its drug Jaypirca (pirtobrutinib), showing a 45% reduction in the risk of disease progression or death for patients with previously treated CLL/SLL when added to a venetoclax regimen. This significant efficacy data strengthens Jaypirca's profile and expands its potential market in hematology-oncology. The news adds to Eli Lilly's recent string of positive developments, including FDA approvals for its weight-loss drug Foundayo and strong financial performance.
At the time of this announcement, LLY was trading at $1,134.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.